Bristol Myers Squibb plans to grow its research and development operations in India. The company’s CEO, Christopher Boerner, mentioned that their newly opened Hyderabad facility is likely to become their biggest unit outside the US by 2025.
This facility, costing $100 million, will hire more than 1,500 employees. Boerner highlighted during his speech at the BioAsia conference that the facility will focus on using digital technologies and artificial intelligence to improve drug development.
Bristol Myers Expands R&D Footprint in India
Bristol Myers, the cancer-focused US drugmaker, is bolstering its research and development endeavors in India. In addition to its Bengaluru center in partnership with Biocon Group’s Syngene International, the company inaugurated a $100-million facility in Hyderabad. CEO Christopher Boerner revealed plans for the Hyderabad facility to become their largest outside the US by 2025, employing over 1,500 staff.
Boerner emphasized the company’s focus on developing next-generation cell therapies for autoimmune diseases like multiple sclerosis, leveraging AI technologies to expedite the process. Furthermore, Bristol Myers intends to make these innovative treatments more accessible, extending their reach to markets including India.
Bristol Myers Expanding Access to Innovative Cancer Therapies in India
Bristol Myers aims to broaden the availability of its groundbreaking cancer treatments, including in emerging markets like India. While the company has not introduced its cancer cell therapies Abecma and Breyanzi in the country, other cancer medications like nivolumab and ipilimumab are marketed as Opdyta and Yervoi, respectively.
Despite inquiries from Reuters regarding the availability of Abecma and Breyanzi in India, the company’s spokesperson has yet to respond. This underscores Bristol Myers’ commitment to enhancing access to cutting-edge therapies, potentially transforming cancer treatment landscapes worldwide.
Bristol Myers Prepares for Patent Expirations Amid Expansion Efforts
Bristol Myers anticipates patent expiration for its top-selling drugs, including the blood thinner Eliquis and cancer immunotherapy Opdivo, in key markets over the next few years. To counter this, the company unveiled a series of deals late last year to replenish its drug development pipeline.
Despite the impending patent losses, Bristol Myers remains committed to its expansion efforts and innovative research and development initiatives. However, the company’s spokesperson has not responded to Reuters’ inquiry regarding the availability of Abecma and Breyanzi in India, highlighting ongoing uncertainties in its global operations.
Bristol Myers has not introduced its cancer cell therapies Abecma and Breyanzi in India as of yet. However, the company offers other cancer medications, such as nivolumab and ipilimumab, marketed as Opdyta and Yervoi, respectively.
Additionally, Bristol Myers collaborates with the Biocon Group’s Syngene International in Bengaluru, operating a research and development center. This strategic partnership underscores the company’s commitment to advancing innovative treatments and fostering scientific advancements in India’s healthcare landscape.
Also Read: Subhash Chandra Not Cooperating on Zee Fund Diversion Probe, Says Sebi
Disney and Reliance Sign Binding Pact for Mega Media Merger in India
SoundPod, Google Pay’s New Payment Innovation, is Here to Take on Paytm’s Soundbox
